Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Elite Feature:   Find Similar Charts in Seconds

Learn How
Market News Market Pulse Stocks News ETF News Crypto News

AEON Biopharma Inc

Contributing Author

Recent Articles by AEON Biopharma Inc

Sep-09
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX AEON GlobeNewswire
Aug-31
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference AEON -5.82% GlobeNewswire
Aug-24
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer AEON GlobeNewswire
Aug-19
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX AEON -19.02% GlobeNewswire
Aug-12
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update AEON GlobeNewswire
Aug-03
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards AEON GlobeNewswire
Jul-14
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding AEON +10.84% GlobeNewswire
Jun-04
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society AEON GlobeNewswire
May-14
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update AEON AEON -9.91% GlobeNewswire
Apr-24
AEON Biopharma Sets Annual Shareholder Meeting AEON GlobeNewswire
Apr-03
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 AEON GlobeNewswire
Apr-03
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards AEON GlobeNewswire
Mar-30
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program AEON -14.70% GlobeNewswire
Mar-25
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program AEON GlobeNewswire
Mar-09
AEON Biopharma Appoints John Bencich as Chief Financial Officer AEON AEON +7.48% GlobeNewswire
Mar-05
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting AEON -5.50% GlobeNewswire
Jan-21
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions AEON +13.33% AEON -13.97% GlobeNewswire
Dec-19
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 AEON +6.93% GlobeNewswire
Dec-15
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong AEON +5.10% AEON +19.21% GlobeNewswire
Nov-20
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling AEON -12.79% GlobeNewswire
Nov-14
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth AEON GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)